Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Cash | 263.05 | 297.81 | - | - |
Cash Equivalents | 118.96 | 7.01 | 405.94 | 700.74 |
Short Term Investments | 3,004.49 | 1,216.79 | 888.40 | 1,316.49 |
Cashand Short Term Investments | 3,386.50 | 1,521.61 | 1,294.34 | 2,017.23 |
Accounts Receivable- Trade Net | 851.43 | 580.95 | 388.17 | 330.61 |
Total Receivables Net | 937.40 | 1,218.41 | 1,110.61 | 566.87 |
Total Inventory | 1,589.11 | 1,530.63 | 1,760.24 | 1,183.54 |
Prepaid Expenses | 60.39 | 33.16 | 136.01 | 36.94 |
Other Current Assets Total | 594.82 | 24.07 | 105.62 | 102.05 |
Total Current Assets | 6,568.23 | 4,327.87 | 4,406.82 | 3,906.64 |
Property/ Plant/ Equipment Total- Gross | 4,102.08 | 3,760.72 | 2,971.83 | 2,436.45 |
Accumulated Depreciation Total | -963.39 | -743.73 | -582.24 | -444.77 |
Property/ Plant/ Equipment Total- Net | 3,138.69 | 3,016.99 | 2,389.59 | 1,991.69 |
Goodwill Net | 20.02 | 20.02 | 20.44 | 20.44 |
Intangibles Net | 1,663.04 | 1,758.42 | 1,874.20 | 18.76 |
Long Term Investments | 316.38 | 363.13 | 263.36 | 233.73 |
Note Receivable- Long Term | 146.01 | 173.49 | 151.44 | 146.44 |
Other Long Term Assets Total | 110.89 | 55.53 | 41.89 | 54.93 |
Total Assets | 11,963.25 | 9,715.45 | 9,147.74 | 6,372.63 |
Accounts Payable | 1,102.99 | 1,008.18 | 1,076.38 | 666.97 |
Notes Payable/ Short Term Debt | 151.47 | 115.02 | 794.59 | 158.35 |
Current Portof LT Debt/ Capital Leases | 23.12 | 27.02 | 26.30 | 20.12 |
Other Currentliabilities Total | 842.15 | 712.91 | 726.20 | 507.95 |
Total Current Liabilities | 2,119.73 | 1,863.14 | 2,623.47 | 1,353.40 |
Long Term Debt | 24.54 | 22.91 | 48.64 | 57.67 |
Capital Lease Obligations | 8.04 | 5.42 | 3.54 | 4.51 |
Total Long Term Debt | 32.58 | 28.32 | 52.18 | 62.18 |
Total Debt | 207.17 | 170.37 | 873.08 | 240.66 |
Deferred Income Tax | 89.07 | 77.31 | 55.62 | 13.03 |
Minority Interest | 212.70 | 188.07 | 161.08 | 140.89 |
Other Liabilities Total | 146.09 | 123.38 | 100.16 | 81.13 |
Total Liabilities | 2,600.17 | 2,280.23 | 2,992.51 | 1,650.63 |
Common Stock Total | 40.06 | 40.06 | 40.06 | 40.06 |
Additional Paid- In Capital | 42.12 | 42.12 | 42.12 | 42.12 |
Retained Earnings( Accumulated Deficit) | 9,270.84 | 7,341.02 | 6,063.95 | 4,632.27 |
Other Equity Total | 10.07 | 12.02 | 9.11 | 7.56 |
Total Equity | 9,363.09 | 7,435.22 | 6,155.23 | 4,722.00 |
Total Liabilities Shareholders' Equity | 11,963.25 | 9,715.45 | 9,147.74 | 6,372.63 |
Total Common Shares Outstanding | 40.06 | 40.06 | 40.06 | 40.06 |
Tangible Book Valueper Share Common Eq | 191.72 | 141.21 | 106.36 | 116.90 |
Mankind Pharma Dividend Mankind Pharma Bonus Mankind Pharma News Mankind Pharma AGM Mankind Pharma Rights Mankind Pharma Splits Mankind Pharma Board Meetings Mankind Pharma Key Metrics Mankind Pharma Shareholdings Mankind Pharma Profit Loss Mankind Pharma Cashflow Mankind Pharma Q1 Results Mankind Pharma Q2 Results Mankind Pharma Q3 Results Mankind Pharma Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks